Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments [Yahoo! Finance]
Alterity Therapeutics Limited - American Depositary Shares (ATHE)
Company Research
Source: Yahoo! Finance
ALTERITY THERAPEUTICS LIMITED – Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes Multiple System Atrophy (MSA) Awareness Month this March and the importance of raising awareness for a devastating and often misunderstood rare neurological disorder with no approved treatment options. MSA is a progressive neurodegenerative disease characterized by a combination of motor impairment, autonomic dysfunction, and rapid loss of independence. Symptoms can include problems with balance, coordination, movement, and blood pressure regulation, and the disease typically progresses quickly following diagnosi
Show less
Read more
Impact Snapshot
Event Time:
ATHE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHE alerts
High impacting Alterity Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ATHE
News
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor [Yahoo! Finance]Yahoo! Finance
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical AdvisorGlobeNewswire
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying TreatmentsGlobeNewswire
- Alterity Therapeutics (NASDAQ:ATHE) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update [Yahoo! Finance]Yahoo! Finance
ATHE
Sec Filings
- 3/4/26 - Form 6-K
- 2/26/26 - Form 6-K
- 1/30/26 - Form 6-K
- ATHE's page on the SEC website